Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer (CRC)
Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes…
- Trial name
- NCT07082335
- Where
- China
- Volunteers
- 679 people
- Sponsor
- Shanghai 10th People's Hospital
Metastatic Colorectal Cancer
Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer
- Trial name
- NCT05004441
- Testing
- Fruquintinib Combined With mFOLFOX6/FOLFIRI
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Zhou Fuxiang
Metastatic Colorectal Cancer (CRC), Volunteer Subjects
Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer
APACOL is a pilot, bicentric, randomised, open-label, prospective, category 2 study. The presence of colon cancer modifies blood lipid parameters which are likely to have an impact on the efficacy of anti-cancer treatments.
- Trial name
- APACOL (NCT06944548)
- Testing
- Lipidomic analyses, Adapted physical activity program
- Where
- 2 sites in France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Colorectal Neoplasms
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC).
- Trial name
- NCT01289821
- Testing
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Colorectal Neoplasms
Stivarga Regulatory Post-Marketing Surveillance Study in Korea
To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.
- Trial name
- StivargaPMS (NCT02106858)
- Testing
- Regorafenib (Stivarga,BAY73-4506)
- Where
- South Korea
- Volunteers
- 316 people
- Sponsor
- Bayer
Locally Advanced or Metastatic Epithelial Tumor
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of…
- Trial name
- NCT04603287
- Testing
- SI-B001
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer Metastatic
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for…
- Trial name
- NCT04169347
- Testing
- Oxaliplatin
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Criterium, Inc.
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies.
- Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07897721
- Testing
- PF-08165784, Fulvestrant, Atirmociclib
- Volunteers
- 268 people
- Sponsor
- Pfizer
Colorectal Cancer, Metastases
Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.
- Trial name
- OLGA (NCT01759238)
- Testing
- Capecitabine, Bevacizumab, Radiotherapy
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or…
- Trial name
- NCT00031616
- Testing
- brivudine phosphoramidate
- Where
- 2 sites in United States
- Sponsor
- NewBiotics
Colorectal Cancer Metastatic
Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy
Cytoreductive surgery with intraperitoneal chemotherapy is one of the most important treatments for patients with colorectal cancer and peritoneal metastasis.
- Trial name
- NCT03503071
- Testing
- Cytoreductive surgery and intraperitoneal chemotherapy
- Where
- South Korea
- Sponsor
- Kyungpook National University Hospital
Neoplasms, Colorectal
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs…
- Trial name
- NCT00536809
- Testing
- lapatinib, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Metastatic, Thromboembolism
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.
- Trial name
- PROTINCOL (NCT05625932)
- Testing
- Tinzaparin
- Where
- 35 sites in Spain
- Volunteers
- 232 people
- Sponsor
- Galician Research Group on Digestive Tumors
HER2 Gene Mutation
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer
The Phase IIa of this clinical study, a dose-escalation study of IAH0968 in combination with CAPEOX, is designed for safety and tolerability in subjects with HER2-positive advanced or metastatic solid tumors.
- Trial name
- NCT05673512
- Testing
- Injection of IAH0968 + CAPEOX
- Where
- China
- Volunteers
- 279 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Metastatic Colon Cancer
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
This is a randomized phase II, open label, two arm study, evaluating the efficacy of panitumumab in combination with Trifluridine-Tipiracilas third line therapy, after a first line containing an anti-EGFR agent panitumumab(at…
- Trial name
- VELO (NCT05468892)
- Testing
- Trifluridine Tipiracil, Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
- Where
- 8 sites in Italy
- Volunteers
- 68 people
- Sponsor
- University of Campania Luigi Vanvitelli
RAS Mutation, Metastatic Colorectal Cancer
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients (according to…
- Conditions
- RAS Mutation, Metastatic Colorectal Cancer, MSS
- Trial name
- NCT06321081
- Testing
- irinotecan, cetuximab, envafolimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital
Colorectal Cancer
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC
This phase II study will evaluate which is the best way to administer cetuximab after recurrence in 1st line irinotecan+bevacizumab based treatment and to obtain results of the efficacy of the oxaliplatin+cetuximab combination as…
- Trial name
- NCT00755534
- Testing
- Irinotecan, Capecitabine, Cetuximab
- Where
- 10 sites in Greece
- Volunteers
- 68 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Adenocarcinoma, CpG Island Methylator Phenotype
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
This phase Ib/II trial studies the side effects and best dose of guadecitabine when given together with nivolumab and to see how well they work in treating participants with colorectal cancer that does not respond to treatment…
- Conditions
- Colorectal Adenocarcinoma, CpG Island Methylator Phenotype, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma
- Trial name
- NCT03576963
- Testing
- Guadecitabine, Nivolumab
- Where
- 2 sites in United States
- Sponsor
- University of Southern California
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.